ReviewFrontiers in immunology2025
Revolutionizing tumor diagnosis and treatment: the promise of DNA nanotechnology.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumors represent a significant challenge to human health, with ongoing difficulties in their diagnosis and treatment. Over recent decades, DNA nanotechnology has emerged as a promising field, demonstrating substantial advancements in drug delivery and disease diagnosis. The inherent biocompatibility and programmability of DNA nanostructures allow for their tailored design and assembly, facilitating the delivery of various therapeutic agents. Due to their ease of modification, these nanostructures can be functionalized to recognize specific targets, enabling the targeted drug delivery and minimizing the adverse effects. Furthermore, DNA nanotechnology contributes to the rapid and sensitive detection of tumor biomarkers, enhancing the early-stage diagnosis of malignant tumors. This article comprehensively reviews advancements in DNA nanomaterial applications for tumor diagnosis and treatment. First of all, in the aspect of tumor diagnosis, this review focuses on the research of DNA nanostructures in the detection of tumor biomarkers, and then introduces the application of DNA nanostructures in tumor therapy, including chemotherapy, gene therapy and immunotherapy. Finally, we summarized the challenges and opportunities of DNA nanomaterials in biomedical research and clinical applications. This review systematically organizes key innovations: (1) first comprehensive analysis of DNA nanostructures design principles for the applications in tumor diagnosis and therapy, and (2) original proposal for overcoming clinical translation barriers through precise design and assembly of DNA nanostructures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.